PREDNISONE TABLETS
Duct Cell Adenocarcinoma of the Pancreas
Edward KimSmall moleculePhase 2Dormant
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 89/ 100
Competitive context
6 Active assets in the Duct Cell Adenocarcinoma of the Pancreas cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Inno-206 University Health Network, Toronto | Phase 2 | BB |
Cediranib National Cancer Institute (NCI) | Phase 2 | BB |
Metformin British Columbia Cancer Agency | Phase 2 | BB |
Selinexor University Health Network, Toronto | Phase 2 | B |
Tas-102 Taiho Pharmaceutical Co., Ltd. | Phase 2 | B |
View all 22 →
Same molecule, other indications
PREDNISONE TABLETS is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →